Lovemore Mapahla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lovemore Mapahla has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Jonny Peter
Allergy and Immunology Unit University of Cape Town Lung Institute Cape Town South Africa
3 shared publications - Lydia Atuhaire
Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
3 shared publications - Peter Suwirakwenda Nyasulu
Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
3 shared publications - Tawanda Chivese
School of Interdisciplinary Arts and Sciences, University of Washington
3 shared publications Thuraya Isaacs
Division of Dermatology, Department of Medicine, University of Cape Town , Cape Town
3 shared publicationsAneliswa Mpungose
Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town
2 shared publications
Latest Publications
- Open Access
- 19 November 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (11) , 2694
Expanding Kelch13 Artemisinin Resistance Markers Are Associated with Higher Malaria Incidence in Uganda
Artemisinin partial resistance (ART-R)-associated Plasmodium falciparum Kelch13 mutations are expanding across Africa. However, their population-level consequences remain poorly understood, particularly in settings of moderate-to-high malaria transmission. We investigated associations between Kelch13 and partner drug mutation prevalence and monthly confirmed malaria incidence across 16 Ugandan districts from 2017 to 2022, using integrated molecular, epidemiological, climatic, malaria-control, and antimalarial resistance data and negative binomial regression. Combined prevalence of WHO-validated and candidate Kelch13 mutations increased over the study period. Each 10-percentage-point increase in Kelch13 prevalence was associated with a 13.1% higher incidence after multivariable adjustment (aIRR, 1.131; 95% CI, 1.090–1.174). Furthermore, each 10-percentage-point increase in pfcrt K76T prevalence was associated with a 24.2% higher malaria incidence. As expected, ITN distribution ≥ 80%, IRS coverage ≥ 90%, and higher altitude were associated with lower incidence, whereas temperatures of 25–30 °C, relative humidity of 60–80%, and higher precipitation were associated with higher incidence. The persistence of these associations after adjustment suggests that expanding ART-R-associated parasite populations are independently associated with malaria incidence. The relationship may be bidirectional. These findings support interpreting ART-R within its ecological and intervention context and integrating molecular, epidemiological, and malaria-control surveillance to safeguard antimalarial efficacy.
- 19 November 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (11) , 2694
Open AccessExpanding Kelch13 Artemisinin Resistance Markers Are Associated with Higher Malaria Incidence in Uganda
Artemisinin partial resistance (ART-R)-associated Plasmodium falciparum Kelch13 mutations are expanding across Africa. However, their population-level consequences remain poorly understood, particularly in settings of moderate-to-high malaria transmission. We investigated associations between Kelch13 and partner drug mutation prevalence and monthly confirmed malaria incidence across 16 Ugandan districts from 2017 to 2022, using integrated molecular, epidemiological, climatic, malaria-control, and antimalarial resistance data and negative binomial regression. Combined prevalence of WHO-validated and candidate Kelch13 mutations increased over the study period. Each 10-percentage-point increase in Kelch13 prevalence was associated with a 13.1% higher incidence after multivariable adjustment (aIRR, 1.131; 95% CI, 1.090–1.174). Furthermore, each 10-percentage-point increase in pfcrt K76T prevalence was associated with a 24.2% higher malaria incidence. As expected, ITN distribution ≥ 80%, IRS coverage ≥ 90%, and higher altitude were associated with lower incidence, whereas temperatures of 25–30 °C, relative humidity of 60–80%, and higher precipitation were associated with higher incidence. The persistence of these associations after adjustment suggests that expanding ART-R-associated parasite populations are independently associated with malaria incidence. The relationship may be bidirectional. These findings support interpreting ART-R within its ecological and intervention context and integrating molecular, epidemiological, and malaria-control surveillance to safeguard antimalarial efficacy.
- Open Access
- 23 October 2026
- Published by SAGE Publications in Journal of Multimorbidity and Comorbidity
- Vol. 16
Development, validation and initial application of a patient-reported outcome measure to assess treatment burden for people living with multimorbidity in low-income settings in South Africa (SIMMBA)
Background: Treatment burden is a key determinant of outcomes for people living with multimorbidity (PLWMM). However, contextually appropriate measures are lacking in low-income settings. We developed and conducted initial validation of the SIMMBA patient-reported outcome measure (PROM) to assess multidimensional treatment burden in South Africa. Methods: Following COSMIN guidelines, items were generated through literature review, expert consultation, and cognitive interviews, and translated into local languages, Afrikaans and IsiXhosa. A cross-sectional study was conducted among 332 adults with multimorbidity attending public primary care clinics in Cape Town. Psychometric evaluation included exploratory factor analysis (EFA), internal consistency (McDonald’s omega and Cronbach’s alpha), test–retest (n=99) reliability (Spearman correlation and intraclass correlation coefficients [ICC]), and differential item functioning (DIF) by gender. Results: Internal consistency was acceptable to good across all domains (ω=0.54–0.83; α=0.643–0.803), except medication burden (ω≈0.21). Most domains showed no evidence of DIF, with two items flagged. Test–retest reliability was predominantly poor to fair (ICC range 0.33–0.55), indicating limited temporal stability. EFA supported a 64% of variance, with generally strong item loadings, although some cross-loadings and low communalities were observed. Participants reported highest burden in the financial domain and lowest in social support. Conclusions: The SIMMBA PROM demonstrates promising preliminary validity in capturing context-specific treatment burden among PLWMM in low-income South African settings. However, further structural refinement, convergent validation, and improved reliability testing are required prior to implementation.
- 23 October 2026
- Published by SAGE Publications in Journal of Multimorbidity and Comorbidity
- Vol. 16
Open AccessDevelopment, validation and initial application of a patient-reported outcome measure to assess treatment burden for people living with multimorbidity in low-income settings in South Africa (SIMMBA)
Background: Treatment burden is a key determinant of outcomes for people living with multimorbidity (PLWMM). However, contextually appropriate measures are lacking in low-income settings. We developed and conducted initial validation of the SIMMBA patient-reported outcome measure (PROM) to assess multidimensional treatment burden in South Africa. Methods: Following COSMIN guidelines, items were generated through literature review, expert consultation, and cognitive interviews, and translated into local languages, Afrikaans and IsiXhosa. A cross-sectional study was conducted among 332 adults with multimorbidity attending public primary care clinics in Cape Town. Psychometric evaluation included exploratory factor analysis (EFA), internal consistency (McDonald’s omega and Cronbach’s alpha), test–retest (n=99) reliability (Spearman correlation and intraclass correlation coefficients [ICC]), and differential item functioning (DIF) by gender. Results: Internal consistency was acceptable to good across all domains (ω=0.54–0.83; α=0.643–0.803), except medication burden (ω≈0.21). Most domains showed no evidence of DIF, with two items flagged. Test–retest reliability was predominantly poor to fair (ICC range 0.33–0.55), indicating limited temporal stability. EFA supported a 64% of variance, with generally strong item loadings, although some cross-loadings and low communalities were observed. Participants reported highest burden in the financial domain and lowest in social support. Conclusions: The SIMMBA PROM demonstrates promising preliminary validity in capturing context-specific treatment burden among PLWMM in low-income South African settings. However, further structural refinement, convergent validation, and improved reliability testing are required prior to implementation.
- Open Access
Expanding Kelch13 artemisinin resistance markers are associated with higher malaria incidence in Uganda
Artemisinin partial resistance (ART-R)-associated Plasmodium falciparum Kelch13 mutations are expanding across Africa. However, their population-level consequences remain poorly understood, particularly in settings of moderate-to-high malaria transmission. We investigated associations between Kelch13 and partner drug mutation prevalence and monthly confirmed malaria incidence across 16 Ugandan districts from 2017 to 2022, using integrated molecular, epidemiological, climatic, malaria-control, and antimalarial resistance data and negative binomial regression. Combined prevalence of WHO-validated and candidate Kelch13 mutations increased over the study period. Each 10-percentage-point increase in Kelch13 prevalence was associated with a 13.1% higher incidence after multivariable adjustment (aIRR 1.131, 95% CI 1.090–1.174). Furthermore, each 10% increase in pfcrt K76T was associated with a 24% increase in malaria transmission. As expected, ITN distribution ≥80%, IRS coverage ≥90%, and higher altitude were associated with lower incidence, whereas temperatures of 25–30°C, relative humidity of 60–80%, and higher precipitation were associated with higher incidence. The persistence of the Kelch13 and pfcrt K76T association after adjustment suggests that expanding ART-R-associated parasite populations are independently associated with malaria incidence. The relationship may be bidirectional. These findings support interpreting ART-R within its ecological and intervention context and integrating molecular, epidemiological, and malaria-control surveillance to safeguard antimalarial efficacy.
Open AccessExpanding Kelch13 artemisinin resistance markers are associated with higher malaria incidence in Uganda
Artemisinin partial resistance (ART-R)-associated Plasmodium falciparum Kelch13 mutations are expanding across Africa. However, their population-level consequences remain poorly understood, particularly in settings of moderate-to-high malaria transmission. We investigated associations between Kelch13 and partner drug mutation prevalence and monthly confirmed malaria incidence across 16 Ugandan districts from 2017 to 2022, using integrated molecular, epidemiological, climatic, malaria-control, and antimalarial resistance data and negative binomial regression. Combined prevalence of WHO-validated and candidate Kelch13 mutations increased over the study period. Each 10-percentage-point increase in Kelch13 prevalence was associated with a 13.1% higher incidence after multivariable adjustment (aIRR 1.131, 95% CI 1.090–1.174). Furthermore, each 10% increase in pfcrt K76T was associated with a 24% increase in malaria transmission. As expected, ITN distribution ≥80%, IRS coverage ≥90%, and higher altitude were associated with lower incidence, whereas temperatures of 25–30°C, relative humidity of 60–80%, and higher precipitation were associated with higher incidence. The persistence of the Kelch13 and pfcrt K76T association after adjustment suggests that expanding ART-R-associated parasite populations are independently associated with malaria incidence. The relationship may be bidirectional. These findings support interpreting ART-R within its ecological and intervention context and integrating molecular, epidemiological, and malaria-control surveillance to safeguard antimalarial efficacy.
- Open Access
Borderless battles: Modelling the spread of artemisinin partial resistance in connected subpopulations in southern Africa
Artemisinin partial resistance has not yet been reported in southern Africa. Therefore, the magnitude of the spread of artemisinin partial resistance in this region is yet to be quantified. Using a two strain metapopulation modelling framework, we explored possible spread of artemisinin partial resistance in eight connected countries with high level of human movement. We explored three scenarios in which artemisinin partial resistance may first enter circulation: low malaria transmission level country; high malaria transmission level country and all countries and compared to an artemisinin partial resistance free scenario. Partial rank correlation coefficient sensitivity analysis was performed to identify key parameters that drive artemisinin partial resistance spread. Our model simulations show that high mobility between countries can increase the spread of mutations associated with delayed clearance. Suggesting that artemisinin partial resistance will be confirmed (>5% partial resistant cases) after 14 years of circulation if it is to appear in southern Africa. We confirm that human movement, both human-to-mosquito and mosquito-to-human probabilities of transmission, were significant and highly sensitive parameters in the spread of artemisinin partial resistance. Human mobility between countries can facilitate the spread of artemisinin partial resistance. More research is needed to identify strategies to preserve the efficacy of artemisinin-based combination therapies in the presence of partial artemisinin resistance, which may eventually lead to treatment failure and necessitate regimen replacement. Author summary: We developed a two-strain, spatially explicit metapopulation model with eight patches of low, moderate and high levels of malaria transmission. We simulated the spread of artemisinin partial resistance in geographically connected Southern African Development Community Malaria Elimination 8 Initiative (SADC-E8) countries with a high-level of human cross border movement. This study provides a hypothetical reference for future studies necessary to fully understand the spread and impact of artemisinin partial resistance in the malaria elimination process in southern Africa. We found that human movement between countries facilitates the spread of artemisinin partial resistance. The slow parasite clearance and high gametocyte carriage (2-fold of sensitive strain 3 days after ACTs treatment) drive the spread of artemisinin partial resistance within the human population. In the absence of artemisinin partial resistance data in SADC-E8, this study’s simulations inform policy to make decisions on the potential spread of artemisinin partial resistance.
Open AccessBorderless battles: Modelling the spread of artemisinin partial resistance in connected subpopulations in southern Africa
Artemisinin partial resistance has not yet been reported in southern Africa. Therefore, the magnitude of the spread of artemisinin partial resistance in this region is yet to be quantified. Using a two strain metapopulation modelling framework, we explored possible spread of artemisinin partial resistance in eight connected countries with high level of human movement. We explored three scenarios in which artemisinin partial resistance may first enter circulation: low malaria transmission level country; high malaria transmission level country and all countries and compared to an artemisinin partial resistance free scenario. Partial rank correlation coefficient sensitivity analysis was performed to identify key parameters that drive artemisinin partial resistance spread. Our model simulations show that high mobility between countries can increase the spread of mutations associated with delayed clearance. Suggesting that artemisinin partial resistance will be confirmed (>5% partial resistant cases) after 14 years of circulation if it is to appear in southern Africa. We confirm that human movement, both human-to-mosquito and mosquito-to-human probabilities of transmission, were significant and highly sensitive parameters in the spread of artemisinin partial resistance. Human mobility between countries can facilitate the spread of artemisinin partial resistance. More research is needed to identify strategies to preserve the efficacy of artemisinin-based combination therapies in the presence of partial artemisinin resistance, which may eventually lead to treatment failure and necessitate regimen replacement. Author summary: We developed a two-strain, spatially explicit metapopulation model with eight patches of low, moderate and high levels of malaria transmission. We simulated the spread of artemisinin partial resistance in geographically connected Southern African Development Community Malaria Elimination 8 Initiative (SADC-E8) countries with a high-level of human cross border movement. This study provides a hypothetical reference for future studies necessary to fully understand the spread and impact of artemisinin partial resistance in the malaria elimination process in southern Africa. We found that human movement between countries facilitates the spread of artemisinin partial resistance. The slow parasite clearance and high gametocyte carriage (2-fold of sensitive strain 3 days after ACTs treatment) drive the spread of artemisinin partial resistance within the human population. In the absence of artemisinin partial resistance data in SADC-E8, this study’s simulations inform policy to make decisions on the potential spread of artemisinin partial resistance.
- Open Access
- 29 May 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1774494
Prospective longitudinal study of psychological sequelae, self-perception of body image, and quality of life in severe cutaneous adverse drug reactions: a case-control study
Background: Severe cutaneous adverse drug reactions (SCARs) are associated with mental health sequelae and reduced quality of life. However, existing research is limited by small retrospective cohorts, overrepresentation of high-income countries, lighter skin tones, inadequate controls, and a paucity of prospective longitudinal case-control studies assessing the psychological sequelae in SCAR. Objective: This study aimed to prospectively determine and compare the longitudinal trajectories of psychological sequelae in patients with SCAR and controls. Methods: Between June 2020 and October 2023, SCAR cases and matched controls were recruited. The following validated instruments were used for assessments: (1) the MINI International Neuropsychiatric Interview to assess depression and suicide risk; (2) the Kessler Psychological Distress Scale (K10) to determine pre-existing depression; (3) the Cutaneous Body Image (CBI) scale to measure self-perception of body image; and (4) the Dermatology quality life index (DQLI) to measure the impact of SCAR on health-related quality of life (QoL). Assessments were conducted at admission (baseline or t 0 ), 6 months ( t 1 ), and 12 months ( t 2 ) after the development of SCARs. Results: Total of 47 SCAR cases (8 SJS/TEN, 35 DRESS, and 4 GBFDE) and 30 controls were recruited. All had Fitzpatrick skin types ≥III. Cases had significantly higher prevalence of depression [21/47 (45%) vs. 4/30 (13.3′%), p = 0.006] and suicide risk [12/21 (57%) vs. 1/4 (25%), p = 0.012] compared to controls at t 0. This was maintained at t 1 and t 2 . Of 45 cases, 36 (80%) had severe negative self-perception, significantly more than in controls [10/18 (56%), p = 0.023] at t 0 . Among the cases, 20% continued to experience this negative self-perception, while 9% experienced a deterioration over time. Only one showed persistent negative self-perception among controls. At t 0, cases had significantly impaired QoL compared to controls , with a median (IQR) DLQI score of [9.3 (4–15) vs. 1.5 (0–3), p < 0.001]. However, this effect was lost over time. A major limitation of the study was the high rate of loss-to-follow-up due to coronavirus disease 2019 (COVID-19). Conclusion: SCARs were found to be associated with a high risk of depression, suicide, impaired QoL, and severe negative self-perception compared to controls. SCAR patients demonstrated persistent or worsening impairments at 6 months and relapses at 12 months. These findings highlight the ongoing psychosocial burden of SCARs and the need for integrated mental health support.
- 29 May 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1774494
Open AccessProspective longitudinal study of psychological sequelae, self-perception of body image, and quality of life in severe cutaneous adverse drug reactions: a case-control study
Background: Severe cutaneous adverse drug reactions (SCARs) are associated with mental health sequelae and reduced quality of life. However, existing research is limited by small retrospective cohorts, overrepresentation of high-income countries, lighter skin tones, inadequate controls, and a paucity of prospective longitudinal case-control studies assessing the psychological sequelae in SCAR. Objective: This study aimed to prospectively determine and compare the longitudinal trajectories of psychological sequelae in patients with SCAR and controls. Methods: Between June 2020 and October 2023, SCAR cases and matched controls were recruited. The following validated instruments were used for assessments: (1) the MINI International Neuropsychiatric Interview to assess depression and suicide risk; (2) the Kessler Psychological Distress Scale (K10) to determine pre-existing depression; (3) the Cutaneous Body Image (CBI) scale to measure self-perception of body image; and (4) the Dermatology quality life index (DQLI) to measure the impact of SCAR on health-related quality of life (QoL). Assessments were conducted at admission (baseline or t 0 ), 6 months ( t 1 ), and 12 months ( t 2 ) after the development of SCARs. Results: Total of 47 SCAR cases (8 SJS/TEN, 35 DRESS, and 4 GBFDE) and 30 controls were recruited. All had Fitzpatrick skin types ≥III. Cases had significantly higher prevalence of depression [21/47 (45%) vs. 4/30 (13.3′%), p = 0.006] and suicide risk [12/21 (57%) vs. 1/4 (25%), p = 0.012] compared to controls at t 0. This was maintained at t 1 and t 2 . Of 45 cases, 36 (80%) had severe negative self-perception, significantly more than in controls [10/18 (56%), p = 0.023] at t 0 . Among the cases, 20% continued to experience this negative self-perception, while 9% experienced a deterioration over time. Only one showed persistent negative self-perception among controls. At t 0, cases had significantly impaired QoL compared to controls , with a median (IQR) DLQI score of [9.3 (4–15) vs. 1.5 (0–3), p < 0.001]. However, this effect was lost over time. A major limitation of the study was the high rate of loss-to-follow-up due to coronavirus disease 2019 (COVID-19). Conclusion: SCARs were found to be associated with a high risk of depression, suicide, impaired QoL, and severe negative self-perception compared to controls. SCAR patients demonstrated persistent or worsening impairments at 6 months and relapses at 12 months. These findings highlight the ongoing psychosocial burden of SCARs and the need for integrated mental health support.
- 7 February 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (7) , 1293-1295
Internal organ involvement in epidermal necrolysis and bullous fixed drug eruption assessed by 18F-fluorodeoxyglucose positron emission tomography and computed tomography: a proof-of-concept study
We investigated internal organ involvement in Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and generalized bullous fixed drug eruption (GBFDE) using 18fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography and computed tomography (PET/CT). Participants (n = 10) underwent scans at two timepoints: acute (t0) and 3 months later (t1). Results showed increased inflammation in multiple organs at t0, with persistent or worsening inflammation in the lungs, eyes and bone marrow at t1. The study confirms internal organ involvement in SJS/TEN and GBFDE and highlights the potential of 18F-FDG PET/CT as a diagnostic tool for tracking inflammation beyond the acute stage.
- 7 February 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (7) , 1293-1295
Internal organ involvement in epidermal necrolysis and bullous fixed drug eruption assessed by 18F-fluorodeoxyglucose positron emission tomography and computed tomography: a proof-of-concept study
We investigated internal organ involvement in Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and generalized bullous fixed drug eruption (GBFDE) using 18fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography and computed tomography (PET/CT). Participants (n = 10) underwent scans at two timepoints: acute (t0) and 3 months later (t1). Results showed increased inflammation in multiple organs at t0, with persistent or worsening inflammation in the lungs, eyes and bone marrow at t1. The study confirms internal organ involvement in SJS/TEN and GBFDE and highlights the potential of 18F-FDG PET/CT as a diagnostic tool for tracking inflammation beyond the acute stage.
- Open Access
- 1 January 2026
- Published by AOSIS in Journal of Public Health in Africa
- Vol. 17 (1) , 8
Admission haemoglobin and albumin as correlates of central nervous system inflammation in rhodesiense human African trypanosomiasis at Rumphi District Hospital, Malawi
Background: Rhodesiense human African trypanosomiasis (rHAT) is an acute zoonotic infection that can rapidly progress to central nervous system (CNS) disease. As lumbar puncture is no longer routinely required for treatment selection, district hospitals need accessible measures associated with CNS inflammatory burden. Aim: This study aimed to evaluate routine admission clinical and laboratory measures as correlates of cerebrospinal-fluid white-cell count and to describe changes in this count during early hospital care. Setting: The study was conducted at Rumphi District Hospital, a public secondary-level treatment facility serving rural communities in the Vwaza Marsh focus of northern Malawi. Methods: We retrospectively studied patients aged ≥ 6 years with parasitological confirmed rHAT from 2012–2024. Cerebrospinal-fluid white-cell counts at admission and Day 11 were analysed using mixed-effects negative binomial regression, reporting adjusted incidence rate ratios (aIRRs) with 95% confidence intervals (CIs). Results: Forty-three patients met the eligibility criteria; 43 contributed admission counts, and 42 contributed Day-11 counts. Day-11 cerebrospinal-fluid white-cell counts were 75% lower than admission counts (aIRR = 0.25, 95% CI: 0.14–0.45; p < 0.001). Stage 2 disease was associated with a higher count than Stage 1 disease (aIRR = 4.23, 95% CI: 1.35–13.30; p = 0.013). Each 1 g/dL increase in haemoglobin and albumin was associated with lower expected counts (haemoglobin aIRR = 0.83, 95% CI: 0.78–0.89; p < 0.001; albumin aIRR = 0.70, 95% CI: 0.54–0.92; p = 0. 009). Conclusion: Lower haemoglobin and albumin were associated with greater cerebrospinal-fluid inflammation, which declined during early care. As accessible admission measures, they may support recognition, triage and monitoring of CNS burden in rHAT, pending prospective diagnostic-accuracy validation before implementation. Contribution: This study links routine blood measures to cerebrospinal-fluid inflammation in rHAT, informing prospective validation priorities.
- 1 January 2026
- Published by AOSIS in Journal of Public Health in Africa
- Vol. 17 (1) , 8
Open AccessAdmission haemoglobin and albumin as correlates of central nervous system inflammation in rhodesiense human African trypanosomiasis at Rumphi District Hospital, Malawi
Background: Rhodesiense human African trypanosomiasis (rHAT) is an acute zoonotic infection that can rapidly progress to central nervous system (CNS) disease. As lumbar puncture is no longer routinely required for treatment selection, district hospitals need accessible measures associated with CNS inflammatory burden. Aim: This study aimed to evaluate routine admission clinical and laboratory measures as correlates of cerebrospinal-fluid white-cell count and to describe changes in this count during early hospital care. Setting: The study was conducted at Rumphi District Hospital, a public secondary-level treatment facility serving rural communities in the Vwaza Marsh focus of northern Malawi. Methods: We retrospectively studied patients aged ≥ 6 years with parasitological confirmed rHAT from 2012–2024. Cerebrospinal-fluid white-cell counts at admission and Day 11 were analysed using mixed-effects negative binomial regression, reporting adjusted incidence rate ratios (aIRRs) with 95% confidence intervals (CIs). Results: Forty-three patients met the eligibility criteria; 43 contributed admission counts, and 42 contributed Day-11 counts. Day-11 cerebrospinal-fluid white-cell counts were 75% lower than admission counts (aIRR = 0.25, 95% CI: 0.14–0.45; p < 0.001). Stage 2 disease was associated with a higher count than Stage 1 disease (aIRR = 4.23, 95% CI: 1.35–13.30; p = 0.013). Each 1 g/dL increase in haemoglobin and albumin was associated with lower expected counts (haemoglobin aIRR = 0.83, 95% CI: 0.78–0.89; p < 0.001; albumin aIRR = 0.70, 95% CI: 0.54–0.92; p = 0. 009). Conclusion: Lower haemoglobin and albumin were associated with greater cerebrospinal-fluid inflammation, which declined during early care. As accessible admission measures, they may support recognition, triage and monitoring of CNS burden in rHAT, pending prospective diagnostic-accuracy validation before implementation. Contribution: This study links routine blood measures to cerebrospinal-fluid inflammation in rHAT, informing prospective validation priorities.
- Open Access
- 20 October 2025
- Published by Frontiers Media SA in Frontiers in Allergy
- Vol. 6, 1664354
Risk factors for angiotensin converting enzyme inhibitor angioedema in a South African population
Introduction: Angiotensin converting enzyme inhibitors (ACEI) have proven mortality and morbidity benefit in hypertension, ischemic heart disease, heart failure, and renal disease and are among the most prescribed medications globally. ACEI angioedema (AE-ACEI) is a potentially life-threatening adverse drug reaction that is reported to occur more frequently in African American populations. However, the clinical profile of AE-ACEI is poorly characterized in diverse African populations.Methods: A case-controlled cohort study with enrolment of AE-ACEI cases and drug-tolerant controls in Cape Town, South Africa. Univariable and multivariable analysis was performed. Controls were defined as patients tolerating ACEI for a minimum of two years. Cases were defined as patients who had angioedema while using an ACEI, patients with a history of angioedema while not on an ACEI were excluded. Cases and controls were recruited from the same demographic areas, including both hospitals and clinics. Information regarding demographics and clinical history was captured via both in person interviews and folder review.Results: A total of 237 AE-ACEI cases, and 466 ACEI tolerant controls were enrolled from seven sites in Cape Town. Features of IgE-mediated immediate drug hypersensitivity were present in 24 cases, which excluded them from analysis. The median age was 58 years (IQR: 47; 67) and 57% were female. AE-ACEI cases more frequently had Black genetic ancestry compared to controls [53% (81/154), vs. 29% (146/407), p < 0.001]. AE-ACEI occurred within 30 days of initiating ACEI therapy in only 31.1% (70/225), with median treatment time to AE-ACEI of 6.9 years (IQR: 2.9; 13). The ACEI tolerant controls were using ACEI for median 9.5 years (IQR: 5; 15.5). All AE-ACEI cases developed swelling above the shoulders, involving the lips and tongue in 72% (165/213) and 50% (107/213) cases respectively. Hospitalisation for AE-ACEI was required in 82% (175/213), however only two patients were intubated, and there were no mortalities. In multivariable analysis traditional risk factors of age, gender, immunosuppression and atopy did not differ between cases and controls. Black genetic ancestry [aOR 15.4 (95% CI 2.94–283), p value = 0.01] and calcium channel blocker use [aOR 1.77 (95% CI 1.17–2.72), p value = 0.008] were significant risk factors for developing AE-ACEI. Cardiac failure, chronic kidney disease, and statin use reduced the risk of AE-ACEI in this model.Conclusion: In this South African population, Black genetic ancestry and calcium channel blocker use were the major risk factors for AE-ACEI. The majority of AE-ACEI occurred after several years of treatment, with most cases involving the lip and/or tongue. Long-term follow-up, genetic, and further mechanistic studies are warranted in additional diverse African populations.
- 20 October 2025
- Published by Frontiers Media SA in Frontiers in Allergy
- Vol. 6, 1664354
Open AccessRisk factors for angiotensin converting enzyme inhibitor angioedema in a South African population
Introduction: Angiotensin converting enzyme inhibitors (ACEI) have proven mortality and morbidity benefit in hypertension, ischemic heart disease, heart failure, and renal disease and are among the most prescribed medications globally. ACEI angioedema (AE-ACEI) is a potentially life-threatening adverse drug reaction that is reported to occur more frequently in African American populations. However, the clinical profile of AE-ACEI is poorly characterized in diverse African populations.Methods: A case-controlled cohort study with enrolment of AE-ACEI cases and drug-tolerant controls in Cape Town, South Africa. Univariable and multivariable analysis was performed. Controls were defined as patients tolerating ACEI for a minimum of two years. Cases were defined as patients who had angioedema while using an ACEI, patients with a history of angioedema while not on an ACEI were excluded. Cases and controls were recruited from the same demographic areas, including both hospitals and clinics. Information regarding demographics and clinical history was captured via both in person interviews and folder review.Results: A total of 237 AE-ACEI cases, and 466 ACEI tolerant controls were enrolled from seven sites in Cape Town. Features of IgE-mediated immediate drug hypersensitivity were present in 24 cases, which excluded them from analysis. The median age was 58 years (IQR: 47; 67) and 57% were female. AE-ACEI cases more frequently had Black genetic ancestry compared to controls [53% (81/154), vs. 29% (146/407), p < 0.001]. AE-ACEI occurred within 30 days of initiating ACEI therapy in only 31.1% (70/225), with median treatment time to AE-ACEI of 6.9 years (IQR: 2.9; 13). The ACEI tolerant controls were using ACEI for median 9.5 years (IQR: 5; 15.5). All AE-ACEI cases developed swelling above the shoulders, involving the lips and tongue in 72% (165/213) and 50% (107/213) cases respectively. Hospitalisation for AE-ACEI was required in 82% (175/213), however only two patients were intubated, and there were no mortalities. In multivariable analysis traditional risk factors of age, gender, immunosuppression and atopy did not differ between cases and controls. Black genetic ancestry [aOR 15.4 (95% CI 2.94–283), p value = 0.01] and calcium channel blocker use [aOR 1.77 (95% CI 1.17–2.72), p value = 0.008] were significant risk factors for developing AE-ACEI. Cardiac failure, chronic kidney disease, and statin use reduced the risk of AE-ACEI in this model.Conclusion: In this South African population, Black genetic ancestry and calcium channel blocker use were the major risk factors for AE-ACEI. The majority of AE-ACEI occurred after several years of treatment, with most cases involving the lip and/or tongue. Long-term follow-up, genetic, and further mechanistic studies are warranted in additional diverse African populations.
- Open Access
- 31 August 2025
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 19 (08) , 1172-1181
Assessing the prevalence of antimicrobial resistance among pediatric patients at Kamuzu Central Hospital, Malawi
Introduction: Severe bacterial infections cause significant disease burden in developing countries, including Malawi. The situation is compounded by the scarcity of resources, inconsistent availability of antibiotics, and increasing antimicrobial resistance (AMR). Methodology: This was a descriptive retrospective study where we analyzed blood culture results of pediatric patients admitted to Kamuzu Central Hospital (KCH), Lilongwe, Malawi. The data from January 2018 to January 2022 were compared with clinical metadata, and analyzed using the statistical software packages STATA version 16.1 and R version 4.2. Results: The data of 272 isolates from blood culture were obtained; 47.8% (130/272) of participants presented with organisms resistant to first-line antibiotics; 13.4% (22/164) were resistant to second-line antibiotics which included resistance to piperacillin/tazobactam and meropenem. Gram-negative isolates constituted 54.3% (89/164) of the isolates, of which 32% (29/89) were Acinetobacter spp; while 45.7% (75/164) of the isolates were Gram-positive of which 42.7% (32/75) was Staphylococcus aureus. There were 12 Escherichia coli isolates, of which 50% (6/12) were highly resistant to piperacillin/tazobactam. The Fisher’s exact test indicated that the antibiotic prescribed after a blood culture test result was significantly associated with the isolate observed (p = 0.016). Conclusions: This study highlights high rates of AMR to commonly used antibiotics in the pediatric ward at KCH, and calls for the need to revise treatment guidelines in the wake of empiric antibiotic choices for pediatric patients, including intensification of maximal use of blood culture tests as part of management of febrile illnesses and reinforcement of antimicrobial stewardship in pediatric patient care.
- 31 August 2025
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 19 (08) , 1172-1181
Open AccessAssessing the prevalence of antimicrobial resistance among pediatric patients at Kamuzu Central Hospital, Malawi
Introduction: Severe bacterial infections cause significant disease burden in developing countries, including Malawi. The situation is compounded by the scarcity of resources, inconsistent availability of antibiotics, and increasing antimicrobial resistance (AMR). Methodology: This was a descriptive retrospective study where we analyzed blood culture results of pediatric patients admitted to Kamuzu Central Hospital (KCH), Lilongwe, Malawi. The data from January 2018 to January 2022 were compared with clinical metadata, and analyzed using the statistical software packages STATA version 16.1 and R version 4.2. Results: The data of 272 isolates from blood culture were obtained; 47.8% (130/272) of participants presented with organisms resistant to first-line antibiotics; 13.4% (22/164) were resistant to second-line antibiotics which included resistance to piperacillin/tazobactam and meropenem. Gram-negative isolates constituted 54.3% (89/164) of the isolates, of which 32% (29/89) were Acinetobacter spp; while 45.7% (75/164) of the isolates were Gram-positive of which 42.7% (32/75) was Staphylococcus aureus. There were 12 Escherichia coli isolates, of which 50% (6/12) were highly resistant to piperacillin/tazobactam. The Fisher’s exact test indicated that the antibiotic prescribed after a blood culture test result was significantly associated with the isolate observed (p = 0.016). Conclusions: This study highlights high rates of AMR to commonly used antibiotics in the pediatric ward at KCH, and calls for the need to revise treatment guidelines in the wake of empiric antibiotic choices for pediatric patients, including intensification of maximal use of blood culture tests as part of management of febrile illnesses and reinforcement of antimicrobial stewardship in pediatric patient care.